Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Open-label Trial Examining the Efficacy, Safety, and Tolerability of Ablative Therapies for High-grade Anal Dysplasia Versus Observation Alone in HIV-positive Men Who Have Sex With Men (MSM)

NCT02503111 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02503111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02503111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Open-label Trial Examining the Efficacy, Safety, and Tolerability of Ablative Therapies for High-grade Anal Dysplasia Versus Observation Alone in HIV-positive Men Who Have Sex With Men (MSM)
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Terminated
Start date
November 30, 2015
Completion date
April 14, 2022
Enrollment
71 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anal dysplasia, human papillomavirus